Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
Public ClinicalTrials.gov record NCT05267262. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in AS Patients With Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients With Primary Steroid-Resistant FSGC
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis
Study identification
- NCT ID
- NCT05267262
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 43 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 14, 2022
- Primary completion
- May 20, 2025
- Completion
- Aug 18, 2025
- Last update posted
- Sep 28, 2025
2022 – 2025
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site | Los Angeles | California | 90022 | — |
| Investigative site | Boca Raton | Florida | 33431 | — |
| Investigative site | Miami | Florida | 33136 | — |
| Investigative site | Riverview | Florida | 33578 | — |
| Investigative site | Atlanta | Georgia | 30322 | — |
| Investigative site | Boston | Massachusetts | 02111 | — |
| Investigative site | Ann Arbor | Michigan | 48109-5718 | — |
| Investigative site | Minneapolis | Minnesota | 55454 | — |
| Investigative Site | Cary | North Carolina | 27511 | — |
| Investigative site | Cleveland | Ohio | 44195 | — |
| Investigative site | Columbus | Ohio | 43235 | — |
| Investigative site | East Providence | Rhode Island | 02914 | — |
| Investigative Site | Dallas | Texas | 75204 | — |
| Investigative site | Houston | Texas | 77054 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
Recently updated Alport Syndrome trials
Other public records listing Alport Syndrome. Sorted by last update posted; newest first. Not a recommendation.
- NCT07211685: A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome Recruiting
- NCT05003986: Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases Recruiting
- NCT04571658: NEPTUNE Match Study Recruiting
- NCT06526741: ASF Alport Patient Registry Recruiting
- NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05267262, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2025 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05267262 live on ClinicalTrials.gov.